Equillium, Inc. — FY2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. This is an annual report; it does not provide standalone fourth-quarter results. Equillium is a clinical-stage biotechnology company with no approved products or product sales.
Business context and programs
The company develops treatments for severe autoimmune and inflammatory diseases. Its clinical-stage candidates are EQ101, a selective inhibitor of IL-2, IL-9 and IL-15; EQ102, an inhibitor of IL-15 and IL-21; and itolizumab (EQ001), an antibody targeting CD6. In February 2022, Equillium acquired Bioniz and the worldwide rights to EQ101 and EQ102. Its principal programs include Phase 2 EQ101 in alopecia areata, Phase 1 EQ102 in healthy volunteers with a planned celiac-disease patient component, Phase 3 itolizumab in acute graft-versus-host disease (aGVHD), and Phase 1b itolizumab in lupus nephritis (LN).
Financial results and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $15.8 million | $0 |
| Research and development expense | $37.5 million | $26.4 million |
| Acquired in-process research and development expense | $23.0 million | $0 |
| General and administrative expense | $17.2 million | $11.4 million |
| Net loss | $62.4 million | $39.1 million |
| Net loss per share, basic and diluted | $1.85 | $1.36 |
| Cash used in operating activities | $8.7 million | $32.1 million |
FY2022 revenue came from Ono-related activity, not product sales: $4.0 million of the upfront payment was recognized over the service period and $11.8 million reflected development funding. Deferred revenue was $25.1 million at year-end, including $14.7 million current. Operating cash use fell year over year, substantially because of Ono-related deferred revenue and noncash acquisition expense; it should not be read as a comparable reduction in underlying operating costs.
At December 31, 2022, cash and cash equivalents were $59.1 million and short-term investments were $11.9 million, totaling $71.0 million. Total liabilities were $46.5 million; notes payable had a carrying amount of $9.0 million, of which $5.7 million was current. The term loan matures June 1, 2024, bears floating-rate interest subject to an 8.25% floor, and includes a 5% final payment fee. The company reported compliance with loan covenants. No meaningful operating margin is presented; the company remains loss-making and has no product revenue.
Material changes and notable items
- Ono paid $26.4 million for an exclusive option to acquire Equillium’s itolizumab rights in the United States, Canada, Australia and New Zealand. If exercised, the option payment is JPY 5.0 billion (about $37.2 million at the filing’s cited March 2023 exchange rate), with up to $101.4 million in potential development and commercialization milestones. Ono funds itolizumab R&D during the option period. The option expires three months after specified EQUALISE and EQUATOR data are delivered, unless terminated earlier.
- The Bioniz acquisition was accounted for as an asset acquisition. Equillium issued 4.82 million shares at closing and recorded $23.0 million of acquired in-process R&D expense. The agreement also provides for contingent shares and potential regulatory and commercial payments.
- Research and development costs rose $11.2 million, mainly from clinical trial start-up and nonclinical expenses; general and administrative costs rose $5.8 million, including business-development legal and consulting costs.
- Common shares outstanding increased to 34.41 million from 29.46 million, primarily reflecting shares issued in the Bioniz acquisition.
- SVB was placed into FDIC receivership on March 10, 2023, after year-end. Equillium reported approximately $8.2 million in an SVB sweep account, regained full access to those funds on March 13, and said most cash was held elsewhere and no material operational impact was expected.
Outlook, risks and contingencies
Management expects year-end 2022 cash, cash equivalents and short-term investments to fund planned operations into 2025, while cautioning that estimates depend on assumptions and may change. The company expects continued operating losses and negative cash flows and says substantial additional funding will be needed to complete development and potential commercialization. Product sales are not expected in the near term, if ever.
Key risks include clinical-trial delays or failure, uncertain safety and efficacy, regulatory approval, patient enrollment, dependence on CROs and contract manufacturers, and reliance on Biocon for itolizumab supply. Ono may terminate the agreement or not exercise its option; if that occurs, Equillium may lose a source of development funding and must fund or partner the program. Other risks include financing needs and potential dilution, intellectual-property protection, reimbursement and pricing, and the requirement for an OFAC general license for itolizumab-related clinical work because of its Cuban-origin intellectual property. Biocon and Bioniz agreements also include substantial contingent milestone and royalty obligations. The filing reports no litigation and no off-balance-sheet arrangements; it states that contingent milestone payments are not reflected on the balance sheet.
Management reported effective disclosure controls and internal control over financial reporting as of December 31, 2022. KPMG issued an unqualified opinion on the consolidated financial statements; it was not engaged to audit internal control over financial reporting.
Important facts for investors to verify
- Whether Ono continues funding the itolizumab program and exercises its option after the specified LN and aGVHD data events; option exercise and milestone amounts remain contingent.
- Whether the stated runway into 2025 remains valid as clinical spending, trial timelines and financing needs evolve.
- Final and complete results from the EQUATOR Phase 3 interim review, EQUALISE LN study, and EQ101 and EQ102 trials; interim or topline results may change.
- The cash-flow impact of Ono funding and deferred revenue, versus recurring operating burn, and the timing of term-loan repayments.
- Potential dilution and contingent obligations tied to the Bioniz acquisition, Biocon license and future capital raises.